Anamorelin Hydrochloride Analysis: Small-Molecule Ghrelin Agonist Sourcing

 

Abstract:

Anamorelin hydrochloride is the only clinically approved small-molecule ghrelin receptor agonist, approved for cancer anorexia-cachexia syndrome. Unlike peptide-based ghrelin mimetics, anamorelin is an orally active synthetic molecule with a distinct chemical identity and synthetic pathway. This analysis examines the sourcing landscape for anamorelin hydrochloride, focusing on its chemical properties, synthetic routes, quality specifications, and the commercial availability of both research-grade and bulk pharmaceutical-grade material. The compound presents unique sourcing considerations due to its status as a controlled research chemical, its complex chiral synthesis, and its narrow therapeutic window requirements for chloride content control.

Introduction

Anamorelin hydrochloride (ONO-7643, RC-1291) represents a breakthrough in the therapeutic targeting of the ghrelin receptor, which has historically proven challenging for drug development. Ghrelin, a 28-amino acid peptide hormone produced primarily in the stomach, stimulates appetite and growth hormone secretion through activation of the growth hormone secretagogue receptor (GHS-R1a). While native ghrelin has a circulating half-life of only minutes, anamorelin was engineered as an orally bioavailable small molecule with a half-life of approximately 7 hours, enabling practical clinical use.

The compound is approved in Japan for cancer cachexia in patients with non-small cell lung cancer, addressing a critical unmet need affecting 50-80% of advanced cancer patients. Its clinical efficacy is characterised by significant improvements in appetite and lean body mass, though notably without corresponding gains in handgrip strength in Phase III trials.

For researchers and pharmaceutical developers, sourcing anamorelin hydrochloride requires navigating a complex landscape of chemical suppliers, quality specifications, and regulatory considerations. This analysis examines the key factors influencing sourcing decisions, from molecular identity through synthetic complexity to commercial availability.

Chemical Identity and Analytical Characterization

Anamorelin hydrochloride is a synthetic piperidine-based compound with the molecular formula C31H43ClN6O3 and a molecular weight of 583.16 g/mol . The compound possesses two chiral centers, both in the (R) configuration, making stereochemical purity a critical quality attribute . The CAS number 861998-00-7 uniquely identifies the hydrochloride salt form .

The compound's chemical name is 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide hydrochloride . This complex structure incorporates an indole moiety (from tryptophan), a benzyl-substituted piperidine ring, and a trimethylhydrazide functional group.

Analytical characterization typically employs high-performance liquid chromatography (HPLC) for purity assessment, with commercial research-grade material specified at ≥98% purity . Nuclear magnetic resonance (NMR) spectroscopy confirms structural identity, while chiral chromatography verifies enantiomeric excess .

Chloride Content and Salt Form Control

A critical sourcing consideration for anamorelin hydrochloride is the precise control of chloride content. The compound is manufactured as the monohydrochloride salt with a theoretical chloride content of 6.08 wt% . However, patent literature reveals that improper synthesis can yield excess chloride, leading to formation of the less stable dihydrochloride salt and compromising long-term stability .

The controlled chloride content specification ranges from 5.8 to 6.2 wt%, with the molar ratio of chloride to anamorelin maintained at or below 1:1 . Methods for achieving this control involve dissolving anamorelin free base in an organic solvent, then reacting with hydrochloric acid under conditions that promote selective monohydrochloride formation through phase separation . The aqueous phase containing the monohydrochloride is then isolated and dried, preferably via spray drying to produce a stable amorphous form with residual solvent levels below 1000 ppm .

For sourcing purposes, buyers should verify that suppliers provide certificates of analysis (COA) documenting chloride content within the specified range. The presence of dihydrochloride can be detected through ion chromatography or potentiometric titration .

Synthetic Routes and Manufacturing Complexity

The synthesis of anamorelin is a multi-step convergent process requiring careful control of stereochemistry. The synthetic route involves preparation of two key intermediates: the chiral (3R)-3-benzyl-3-(trimethylhydrazinecarbonyl)piperidine moiety and the N-protected dipeptide Boc-L-α-aminoisobutyryl-L-tryptophan .

The piperidine intermediate synthesis begins with N-Boc protection of ethyl nipecotate, followed by stereoselective benzylation using lithium diisopropylamide (LDA) to form the enolate, then benzyl bromide addition . Saponification yields the carboxylic acid, which is resolved using a chiral amine such as R-(+)-1-phenethylamine. The chiral acid is then activated and coupled with trimethylhydrazine, followed by Boc deprotection.

Recent innovations have focused on green chemistry approaches to this synthesis. A 2025 protocol demonstrated a complete green synthesis achieving 65% overall yield while eliminating all carcinogenic, mutagenic, and reprotoxic substances . This approach replaces traditional benzyl chloroformate protection with Boc chemistry, substitutes methyl iodide methylation with dimethyl carbonate under flow conditions, and employs bio-based solvents including 2-methyltetrahydrofuran and cyclopentyl methyl ether . The protocol achieved 82% waste reduction and 34% lower manufacturing costs compared to conventional routes.

For sourcing purposes, the synthetic complexity means that only specialized manufacturers with chiral synthesis capabilities can produce anamorelin hydrochloride at pharmaceutical grade. The presence of two stereocenters requires rigorous enantiomeric purity testing, as the wrong stereoisomer may have reduced or altered receptor activity .

Commercial Sourcing Landscape

The current market for anamorelin hydrochloride reflects its dual status as a research chemical and a clinically approved pharmaceutical. Research-grade material is available from numerous chemical suppliers at varying price points. MedChemExpress offers the compound with 98.94% purity documented by HPLC . CymitQuimica supplies anamorelin hydrochloride as a reference standard from TRC (Toronto Research Chemicals) at 99.10% minimum purity . Pricing ranges from approximately $23 for 1 mg to $186 for 100 mg from research chemical suppliers, with Biosynth listing 5 mg at $900.00 for their premium reference-grade material .

Bulk pharmaceutical-grade sourcing presents different considerations. The Chinese market shows active supply from manufacturers such as Hubei Chenxin Chemical, which lists anamorelin hydrochloride at 99% HPLC purity with quantities up to 25 kg available . These suppliers typically serve as contract manufacturing organizations or API distributors for pharmaceutical development.

Critical sourcing considerations include:

• Chiral purity verification: Ensure suppliers provide enantiomeric excess data, typically >99.5% for pharmaceutical applications

• Chloride content specification: Request COA documenting chloride content within 5.8-6.2 wt%

• Residual solvent profiles: Confirm compliance with ICH guidelines, particularly for solvents used in synthesis

• Documentation: For pharmaceutical use, suppliers should provide Drug Master File (DMF) support and regulatory documentation

The research-grade market is characterized by small quantities and high per-milligram costs, while bulk sourcing requires establishing relationships with API manufacturers capable of multi-kilogram production under cGMP conditions.

Conclusion

Anamorelin hydrochloride occupies a unique position in the ghrelin receptor agonist landscape as the only approved small-molecule therapeutic in this class. Sourcing the compound requires careful attention to its complex chiral synthesis, precise chloride content control, and the distinction between research-grade and pharmaceutical-grade specifications. The emergence of green synthesis protocols offers the prospect of more sustainable and cost-effective manufacturing, potentially improving accessibility. For researchers and developers, successful sourcing depends on rigorous supplier qualification, comprehensive analytical verification, and clear understanding of the regulatory requirements applicable to their intended use. As the clinical evidence for anamorelin continues to accumulate in cancer cachexia and potentially other catabolic conditions, demand for high-quality material will likely increase, reinforcing the importance of reliable sourcing strategies.